|
1
|
Essouma M and Noubiap JJ: Therapeutic
potential of folic acid supplementation for cardiovascular disease
prevention through homocysteine-lowering and blockade in rheumatoid
arthritis patients. Biomark Res. 3(24)2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hayta E, Hizmetli S, Atalar MH and Çinar
Z: Association of plasma homocysteine level and carotid
intima-media thickness in rheumatoid arthritis patients receiving
methotrexate. Arch Rheumatol. 3:214–220. 2015.
|
|
3
|
Yang X, Gao F and Liu Y: Association of
homocysteine with immunological-inflammatory and metabolic
laboratory markers and factors in relation to hyperhomocysteinaemia
in rheumatoid arthritis. Clin Exp Rheumatol. 33:900–903.
2015.PubMed/NCBI
|
|
4
|
Snow MH and Mikuls TR: Rheumatoid
arthritis and cardiovascular disease: The role of systemic
inflammation and evolving strategies of prevention. Curr Opin
Rheumatol. 17:234–241. 2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Pleșa CF, Nicolae C, Sîrbu CA, Nemeș R,
Păunescu A and Țânțu MM: Use of anticoagulants in cerebral vascular
pathology:. Farmacia. 67:27–33. 2019.
|
|
6
|
Maradit-Kremers H, Nicola PJ, Crowson CS,
Ballman KV and Gabriel SE: Cardiovascular death in rheumatoid
arthritis: A population-based study. Arthritis Rheum. 52:722–732.
2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lim TK, Lim E, Dwivedi G, Kooner J and
Senior R: Normal value of carotid intima-media thickness-a
surrogate marker of atherosclerosis: Quantitative assessment by
B-mode carotid ultrasound. J Am Soc Echocardiogr. 21:112–126.
2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
del Rincón I, Williams K, Stern MP,
Freeman GL, O'Leary DH and Escalante A: Association between carotid
atherosclerosis and markers of inflammation in rheumatoid arthritis
patients and healthy subjects. Arthritis Rheum. 48:1833–1840.
2003.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Simon A, Gariepy J, Chironi G, Megnien JL
and Levenson J: Intima-media thickness: A new tool for diagnosis
and treatment of cardiovascular risk. J Hypertens. 20:159–169.
2002.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Popa C, Netea MG, van Riel PL, van der
Meer JW and Stalenhoef AF: The role of TNF-alpha in chronic
inflammatory conditions, intermediary metabolism, and
cardiovascular risk. J Lipid Res. 48:751–762. 2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Linton MF, Yancey PG, Davies SS, Jerome
WG, Linton EF, Song WL, Doran AC and Vickers KC: The role of lipids
and lipoproteins in atherosclerosis. In: Endotext. Feingold KR,
Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan
K, Grossman A, Hershman JM, Hofland J, et al (eds).
MDText.com, Inc, South Dartmouth, MA, 2019.
|
|
12
|
Giles JT, Post W, Blumenthal RS and Bathon
JM: Therapy insight: Managing cardiovascular risk in patients with
rheumatoid arthritis. Nat Clin Pract Rheumatol. 2:320–329.
2006.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Skeoch S, Cristinacce PLH, Williams H,
Pemberton P, Xu D, Sun J, James J, Yuan C, Hatsukami T, Hockings
PD, et al: Imaging atherosclerosis in rheumatoid arthritis:
Evidence for increased prevalence, altered phenotype and a link
between systemic and localised plaque inflammation. Sci Rep.
7(827)2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hadi HA, Carr CS and Al Suwaidi J:
Endothelial dysfunction: Cardiovascular risk factors, therapy, and
outcome. Vasc Health Risk Manag. 3:183–198. 2005.PubMed/NCBI
|
|
15
|
Saposnik G: The role of vitamin B in
stroke prevention: A journey from observational studies to clinical
trials and critique of the VITAmins TO Prevent Stroke (VITATOPS).
Stroke. 42:838–842. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Selhub J: The many facets of
hyperhomocysteinemia: Studies from the Framingham cohorts. J Nutr.
136 (Suppl 6):1726S–1730S. 2006.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Alvarez B, Yugueros X, Fernández E,
Luccini F, Gené A and Matas M: Relationship between plasma
homocysteine and the morphological and immunohistochemical study of
carotid plaques in patients with carotid stenosis over 70%. Ann
Vasc Surg. 26:500–505. 2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Eikelboom JW, Hankey GJ, Anand SS,
Lofthouse E, Staples N and Baker RI: Association between high
homocyst(e)ine and ischemic stroke due to large- and small-artery
disease but not other etiologic subtypes of ischemic stroke.
Stroke. 5:1069–1075. 2000.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wu GH, Kong FZ, Dong XF, Wu DF, Guo QZ and
Shen AR: Association between hyperhomocysteinemia and stroke with
atherosclerosis and small artery occlusion depends on homocysteine
metabolism-related vitamin levels in Chinese patients with normal
renal function. Metab Brain Dis. 3:859–865. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Guin A, Chatterjee Adhikari M, Chakraborty
S, Sinhamahapatra P and Ghosh A: Effects of disease modifying
anti-rheumatic drugs on subclinical atherosclerosis and endothelial
dysfunction which has been detected in early rheumatoid arthritis:
1-year follow-up study. Semin Arthritis Rheum. 43:48–54.
2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kotani K, Miyamoto M and Ando H: The
effect of treatments for rheumatoid arthritis on endothelial
dysfunction evaluated by flow-mediated vasodilation in patients
with rheumatoid arthritis. Curr Vasc Pharmacol. 15:10–18.
2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sattin M and Towheed T: The effect of
TNFα-inhibitors on cardiovascular events in patients with
rheumatoid arthritis: An updated systematic review of the
literature. Curr Rheumatol Rev. 12:208–222. 2016.PubMed/NCBI
|
|
23
|
Popa C, Netea MG, Radstake T, Van der Meer
JW, Stalenhoef AF, van Riel PL and Barerra P: Influence of
anti-tumour necrosis factor therapy on cardiovascular risk factors
in patients with active rheumatoid arthritis. Ann Rheum Dis.
2:303–305. 2005.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Dixon WG, Watson KD, Lunt M and Hyrich KL:
British Society for Rheumatology Biologics Register Control Centre
Consortium. Silman AJ and Symmons DP: British Society for
Rheumatology Biologics Register. Reduction in the incidence of
myocardial infarction in patients with rheumatoid arthritis who
respond to anti-tumor necrosis factor alpha therapy: Results from
the British society for rheumatology biologics register. Arthritis
Rheum. 56:2905–2912. 2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Aletaha D, Neogi T, Silman AJ, Funovits J,
Felson DT, Bingham CO Jr, Birnbaum NS, Burmester GR, Bykerk VP,
Cohen MD, et al: 2010 Rheumatoid arthritis classification criteria:
An American college of rheumatology/european league against
rheumatism collaborative initiative. Arthritis Rheum. 62:2569–2581.
2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kang SS, Wong PW and Malinow MR:
Hyperhomocyst(e)inemia as a risk factor for occlusive vascular
disease. Annu Rev Nutr. 12:279–298. 1992.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Roubenoff R, Dellaripa P, Nadeau MR, Abad
LW, Muldoon BA, Selhub J and Rosenberg IH: Abnormal homocysteine
metabolism in rheumatoid arthritis. Arthritis Rheum. 40:718–722.
1997.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Haagsma CJ, Blom HJ, van Riel PL, van't
Hof MA, Giesendorf BA, van Oppenraaij-Emmerzaal D and van de Putte
LB: Influence of sulphasalazine, methotrexate, and the combination
of both on plasma homocysteine concentrations in patients with
rheumatoid arthritis. Ann Rheum Dis. 58:79–84. 1999.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yang HT, Lee M, Hong KS, Ovbiagele B and
Saver JL: Efficacy of folic acid supplementation in cardiovascular
disease prevention: An updated meta-analysis of randomized
controlled trials. Eur J Intern Med. 23:745–754. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Gonzalez-Gay MA, Gonzalez-Juanatey C,
Piñeiro A, Garcia-Porrua C, Testa A and Llorca J: High-grade
C-reactive protein elevation correlates with accelerated
atherogenesis in patients with rheumatoid arthritis. J Rheumatol.
32:1219–1223. 2005.PubMed/NCBI
|
|
31
|
Morgan SL, Baggott JE, Lee JY and Alarcón
GS: Folic acid supplementation prevents deficient blood folate
levels and hyperhomocysteinemia during longterm, low dose
methotrexate therapy for rheumatoid arthritis: Implications for
cardiovascular disease prevention. J Rheumatol. 25:441–446.
1998.PubMed/NCBI
|
|
32
|
Ridker PM, Cushman M, Stampfer MJ, Tracy
RP and Hennekens CH: Inflammation, aspirin, and the risk of
cardiovascular disease in apparently healthy men. N Engl J Med.
336:973–979. 1997.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ballantyne CM, Hoogeveen RC, Bang H,
Coresh J, Folsom AR, Heiss G and Sharrett AR:
Lipoprotein-associated phospholipase A2, high-sensitivity
C-reactive protein, and risk for incident coronary heart disease in
middle-aged men and wome in the atherosclerosis risk in communities
(ARIC) study. Circulation. 109:837–842. 2004.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Elliott P, Chambers JC, Zhang W, Clarke R,
Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, Bennett D,
et al: Genetic loci associated with C-reactive protein levels and
risk of coronary heart disease. JAMA. 302:37–48. 2009.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Virani SS, Pompeii L, Lincoln AE, Dunn RE,
Tucker AM, Nambi V, Nasir K, Vogel RA, Boone JL, Roberts AJ and
Ballantyne CM: Association between traditional cholesterol
parameters, lipoprotein particle concentration, novel biomarkers
and carotid plaques in retired national football league players.
Atherosclerosis. 222:551–556. 2012.PubMed/NCBI View Article : Google Scholar
|
